BCYC News and Press, Bicycle Therapeutics plc From 07/13/21

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology - Exclusive rights to innovative peptide technology positions Ionis to further strengthen targeting capabilities of its LICA therapies PR Newswire CARLSB...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced an update regarding shareholder attendance at its 2021 Annual General Me...

Bicycle Therapeutics (BCYC): Q1 GAAP EPS of -$0.73 misses by $0.05.Revenue of $1.8M (+59.3% Y/Y) beats by $0.15M.Press Release For further details see: Bicycle Therapeutics EPS misses by $0.05, beats on revenue

- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ...

- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bi...

- First milestone achieved in neuroscience collaboration with Dementia Discovery Fund and the Alzheimer’s Research UK Oxford Drug Discovery Institute - Significant advances made in the application of Bicycle technology against emerging antimicrobial and antiviral ta...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Jose-Carlos (“JC”) Gutierrez-Ramos,...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in a fireside chat at the Oppenheim...

Bicycle Therapeutics (BCYC): Q4 GAAP EPS of -$0.83 misses by $0.32.Revenue of $3.85M (-27.1% Y/Y) beats by $0.19M.Press Release For further details see: Bicycle Therapeutics EPS misses by $0.32, beats on revenue

- Significant progress achieved across pipeline of Bicycle ® Toxin Conjugates (BTCs™) and tumor targeted immune cell agonists (TICAs™) - Cash of $136.0 million at December 31, 2020 expected to provide financial runway through multiple clinical milestones...